These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1704264

  • 1. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
    Steis RG, Smith JW, Urba WJ, Venzon DJ, Longo DL, Barney R, Evans LM, Itri LM, Ewel CH.
    Blood; 1991 Feb 15; 77(4):792-8. PubMed ID: 1704264
    [Abstract] [Full Text] [Related]

  • 2. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL.
    N Engl J Med; 1988 Jun 02; 318(22):1409-13. PubMed ID: 3367950
    [Abstract] [Full Text] [Related]

  • 3. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.
    von Wussow P, Pralle H, Hochkeppel HK, Jakschies D, Sonnen S, Schmidt H, Müller-Rosenau D, Franke M, Haferlach T, Zwingers T.
    Blood; 1991 Jul 01; 78(1):38-43. PubMed ID: 2070058
    [Abstract] [Full Text] [Related]

  • 4. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
    Bekisz JB, zur Nedden DL, Enterline JC, Zoon KC.
    J Interferon Res; 1989 Sep 01; 9 Suppl 1():S1-7. PubMed ID: 2809275
    [Abstract] [Full Text] [Related]

  • 5. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ, Jacobs SL, Treuhaft MW.
    J Interferon Res; 1989 Sep 01; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [Abstract] [Full Text] [Related]

  • 6. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients.
    Gastl G, Werter M, De Pauw B, Nerl C, Aulitzky W, von Lüttichau I, Tilg H, Thaler J, Lang A, Abbrederis K.
    Leukemia; 1989 Jun 01; 3(6):453-60. PubMed ID: 2725061
    [Abstract] [Full Text] [Related]

  • 7. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells.
    Billard C, Sigaux F, Castaigne S, Valensi F, Flandrin G, Degos L, Falcoff E, Aguet M.
    Blood; 1986 Mar 01; 67(3):821-6. PubMed ID: 2936410
    [Abstract] [Full Text] [Related]

  • 8. Different antitumor mechanisms of interferon-alpha in the treatment of hairy cell leukemia and renal cell cancer.
    Porzsolt F, Digel W, Jacobsen H, Mittnacht S, Kirchner H, Heimpel H.
    Cancer; 1988 Jan 15; 61(2):288-93. PubMed ID: 3334965
    [Abstract] [Full Text] [Related]

  • 9. [Anti-interferon antibody in chronic hepatitis C].
    Arai K, Shindo M, Okuno T.
    Nihon Rinsho; 1994 Jul 15; 52(7):1929-34. PubMed ID: 7521441
    [Abstract] [Full Text] [Related]

  • 10. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.
    Smith JW, Longo DL, Urba WJ, Clark JW, Watson T, Beveridge J, Conlon KC, Sznol M, Creekmore SP, Alvord WG.
    Blood; 1991 Oct 01; 78(7):1664-71. PubMed ID: 1912555
    [Abstract] [Full Text] [Related]

  • 11. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC.
    Cancer Res; 1990 Aug 01; 50(15):4588-94. PubMed ID: 2114942
    [Abstract] [Full Text] [Related]

  • 12. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.
    Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B.
    Blood; 1990 Feb 15; 75(4):839-45. PubMed ID: 2302457
    [Abstract] [Full Text] [Related]

  • 13. A biological approach to optimize interferon treatment in hairy cell leukemia.
    Gastl G, Aulitzky W, Tilg H, Nachbaur K, Troppmair J, Flener R, Huber C.
    Immunobiology; 1986 Sep 15; 172(3-5):262-8. PubMed ID: 3804368
    [Abstract] [Full Text] [Related]

  • 14. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
    Russo D, Candoni A, Zuffa E, Minisini R, Silvestri F, Fanin R, Zaja F, Martinelli G, Tura S, Botta G, Baccarani M.
    Br J Haematol; 1996 Aug 15; 94(2):300-5. PubMed ID: 8759890
    [Abstract] [Full Text] [Related]

  • 15. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
    Antonelli G, Currenti M, Turriziani O, Dianzani F.
    J Infect Dis; 1991 Apr 15; 163(4):882-5. PubMed ID: 1901335
    [Abstract] [Full Text] [Related]

  • 16. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
    Dummer R, Müller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G.
    Cancer; 1991 May 01; 67(9):2300-4. PubMed ID: 1901514
    [Abstract] [Full Text] [Related]

  • 17. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
    Nielsen B, Hokland M, Justesen J, Hasselbalch H, Ellegaard J, Hokland P.
    Eur J Haematol; 1989 Jan 01; 42(1):50-9. PubMed ID: 2914594
    [Abstract] [Full Text] [Related]

  • 18. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
    Aulitzky W, Gastl G, Troppmair J, Tilg H, Abbrederis K, Nerl C, Flener R, Rokos H, Huber C.
    Acta Med Austriaca; 1985 Jan 01; 12(5):115-21. PubMed ID: 3832745
    [Abstract] [Full Text] [Related]

  • 19. High titer of interferon (IFN)-neutralizing antibody in a patient with glioblastoma treated with IFN-alpha. Case report.
    Otsuka S, Handa H, Yamashita J.
    J Neurosurg; 1984 Sep 01; 61(3):591-3. PubMed ID: 6086859
    [Abstract] [Full Text] [Related]

  • 20. In vivo induction of proteins during therapy of hairy cell leukemia with alpha-interferon.
    Samuels BL, Golomb HM, Brownstein BH.
    Blood; 1987 Jun 01; 69(6):1570-3. PubMed ID: 3580566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.